Chemotherapy plus radiation treatment is effective in controlling stage IA or IIA nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment-related deaths. Chemotherapy ...

BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for ...

There are other recent examples of smaller clinical trials in HL and controversial follow-up reports. The Canadian HD.6 study randomly assigned 405 patients with stage IA or IIA nonbulky HL to either ...

Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients ...

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, ...

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. Between 1989 and 1993 ...

Older patients with early-stage Hodgkin's lymphoma (HL) have a tough time handling the standard regimen of 4 cycles of ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) ...

Patients with advanced classical Hodgkin lymphoma treated with first line brentuximab vedotin (Adcetris) plus chemotherapy showed substantial improvements in overall survival compared with those ...

To participate in this study, patients were required to have newly diagnosed cHL, treated with ABVD with or without radiation and be followed at the Mayo Clinic (Rochester, MN, USA). Patients ...

Please provide your email address to receive an email when new articles are posted on . Patients with HIV-associated Hodgkin’s lymphoma had a similar prognosis to non-HIV infected Hodgkin’s lymphoma ...

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017. Phase 3 results from the ECHELON-1 study, presented at the 59th Annual Meeting & ...